Next-generation sequencing revolutionizes genomics by enabling massively parallel DNA and RNA analysis, accelerating research from cancer genomics to rare disease diagnostics. The next-generation sequencing market size was valued at USD 12.65 billion in 2025 and is projected to grow from USD 14.88 billion in 2026 to USD 56.07 billion by 2034 at a CAGR of 18.03% during the forecast period (2026-2034), as per Straits Research Analysis.

 

Market Drivers

Precision oncology demands comprehensive genomic profiling identifying actionable mutations in 40% of advanced cancer cases guiding targeted therapies and immunotherapies. Declining sequencing costs from USD 100 million per genome in 2001 to USD 600 today democratizes access enabling population-scale studies and direct-to-consumer testing.

Regulatory approvals for companion diagnostics and liquid biopsy assays expand clinical adoption with 500+ NGS-based tests receiving FDA clearance.

Market Challenges

Bioinformatics complexity requires high-performance computing infrastructure processing 100TB datasets with variant calling accuracy exceeding 99.9%. Data privacy regulations including GDPR and HIPAA mandate secure storage of 1 exabyte annual genomic data generation. 

Standardization gaps across platforms create reproducibility challenges hindering clinical validation studies.

 

Get Your Sample Report Here: https://straitsresearch.com/report/next-generation-sequencing-market/request-sample

Market Segmentation

By Product Type

Sequencing platforms dominate revenue with short-read systems processing 400 million reads per run. Consumables grow rapidly including library prep kits and flow cells representing 60% recurring revenue.

Bioinformatics software enables variant annotation and structural variant detection.

By Technology

Short-read sequencing leads with Illumina's sequencing-by-synthesis delivering 30X whole genome coverage. Long-read platforms including PacBio HiFi and Oxford Nanopore PromethION excel in structural variant detection and phasing.

By Application

Oncology commands largest share profiling 2 million tumors annually for therapy selection. Rare disease diagnostics identify causative variants in 40% undiagnosed cases.

Infectious disease surveillance sequences SARS-CoV-2 variants in real-time across 100+ countries.

By End User

Research institutions hold majority share conducting discovery genomics. Clinical labs grow fastest with CAP/CLIA accreditation supporting therapeutic decision-making.

Pharma/biotech utilizes NGS for drug discovery target identification.

By Region

North America leads with NIH funding and 1000+ CLIA labs. Europe emphasizes population genomics through UK Biobank and Finland's FinnGen. Asia Pacific accelerates via China's 1 million genome initiative.

Top 10 Competitors in the Next-generation Sequencing Market

  1. Illumina Inc. – Market leader with NovaSeq X generating 16TB per run and 98% market share in short-read sequencing.

  2. Thermo Fisher Scientific Inc. – Ion Torrent Genexus delivering turnkey NGS-to-report in 24 hours for clinical labs.

  3. Pacific Biosciences of California Inc. – Revio HiFi system achieving Q40 accuracy for complete human genome assembly.

  4. Oxford Nanopore Technologies Ltd. – PromethION 2 achieving 290Gb real-time sequencing with direct RNA capability.

  5. Element Biosciences Inc. – AVITI delivering 1.6B reads with 95% cluster utilization efficiency.

  6. MGI Tech Co. Ltd. – DNBSEQ-T20x2 supporting 4Tb daily throughput at 1/3 Illumina pricing.

  7. Qiagen N.V. – QIAseq panels with unique molecular indices eliminating PCR duplicates in liquid biopsy.

  8. Roche Holding AG – Sequencing unit with Roche NimbleGen hybridization capture technology.

  9. BGI Genomics – Complete genomics division offering DNBSEQ ultra-high throughput systems.

  10. 10x Genomics Inc. – Chromium platforms enabling single-cell RNA sequencing at 100,000 cells per run.

These companies drive innovation through single-molecule real-time sequencing, direct detection, and spatial transcriptomics integration.

About Us

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.